#None #Harbour BioMed #Spruce Biosciences #HBM Alpha Therapeutics

Harbour BioMed and Spruce Biosciences: A Growing Partnership

In a significant move in the biopharmaceutical landscape, Harbour BioMed (HKEX: 02142), a prominent global company focused on antibody therapeutics, has made headlines by exercising its warrant to acquire common stock in Spruce Biosciences, Inc. (Nasdaq: SPRB). This acquisition not only enhances Harbour's stake in Spruce but also marks a pivotal advancement in their collaborative efforts.

As of January 18, 2026, Harbour BioMed now holds about 3.8% of the total outstanding shares and approximately 3.1% of the fully diluted shares of Spruce Biosciences. This transaction signals more than just a financial investment; it embodies a deepened strategic partnership that has evolved beyond a traditional licensor-licensee relationship.

Dr. Jingsong Wang, the Founder and CEO of Harbour BioMed, expressed optimism regarding this development, stating, "This warrant exercise marks a significant milestone in our relationship with Spruce Biosciences. It moves us beyond a traditional licensor-licensee relationship to a truly aligned strategic partnership, reinforcing our shared commitment to accelerating the development of transformative therapies for patients worldwide." This reaffirms both companies' dedication to advancing innovative treatments in immunology and oncology, particularly under the collaborative umbrella of HBM Alpha Therapeutics (HBMAT).

HBMAT, an innovative biotechnology firm incubated by Harbour BioMed, plays a crucial role in the collaboration with Spruce, particularly in the development of a monoclonal antibody known as SPR202. This antibody has shown promise in addressing disorders such as congenital adrenal hyperplasia, demonstrating the potential impact of their joint endeavors in enhancing patient outcomes.

The Significance of the Collaboration

The collaboration between Harbour BioMed and Spruce Biosciences is not merely a financial transaction; it reflects a shared vision for the future of biotech. With the competition in therapeutic antibody development intensifying, this partnership aims to leverage the strengths of both entities to expedite the creation of innovative treatments.

Harbour BioMed is recognized for its robust pipeline of novel antibody therapeutics, driven by its proprietary technology platform, Harbour Mice®. This platform is instrumental in developing fully human monoclonal antibodies, providing the foundation for the advanced biopharmaceuticals Harbour aims to deliver. The HCAb-based immune cell engagers and antagonists take the technology a step further, enabling the creation of biologics that can target diseases more effectively than traditional therapies.

The strategic acquisition of stock is a testament to Harbour BioMed’s confidence in Spruce and the collaborative project's potential. By securing a stronger financial and operational foothold in Spruce, Harbour positions itself to play a more active and influential role in guiding the development of critical therapies.

Looking Ahead

Looking towards the future, the collaboration holds substantial promise. The ongoing development of SPR202 and potential upcoming projects through HBMAT can lead to groundbreaking advancements in healthcare treatments. As the global biopharmaceutical market continues to evolve, partnerships like this one are likely to be pivotal in driving innovation and improving patient care.

As Harbour BioMed strengthens its relationship with Spruce Biosciences, stakeholders and the medical community will be keenly observing how these collaborative efforts unfold. The ongoing commitment to advancing therapies through shared expertise could yield transformative solutions for various health challenges, marking a new chapter in the biopharmaceutical industry.

In summary, Harbour BioMed's acquisition of common stock in Spruce Biosciences represents a notable transition towards a more synergistic partnership, one that is set to enhance their capabilities and broaden their impact on global health.